Patents by Inventor Anne Dejean

Anne Dejean has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7622266
    Abstract: A method for identifying a synthetic ligand for retinoic acid receptor ? comprises providing a sample, including a synthetic compound, exposing the sample to cultured cells, wherein the cultured cells comprise RAR?, determining if transcriptional expression of a gene encoding RAR? is upregulated compared to transcriptional expression of a control gene, and choosing a sample that upregulates the expression of RAR? as being a synthetic ligand for RAR?.
    Type: Grant
    Filed: March 21, 2006
    Date of Patent: November 24, 2009
    Assignee: Institut Pasteur
    Inventors: Hugues Blaudin de The, Agnes Marchio, Pierre Tiollais, Anne Dejean
  • Publication number: 20060189798
    Abstract: A previously isolated hepatitis B virus (HBV) integration in a 147 bp cellular DNA fragment linked to hepatocellular carcinoma (HCC) was used as a probe to clone the corresponding complementary DNA from a human liver cDNA library. Nucleotide sequence analysis revealed that the overall structure of the cellular gene, which has been named hap, is similar to that of the DNA-binding hormone receptors. Six out of seven hepatoma and hepatoma-derived cell-lines express a 2.5 kb hap mRNA species which is undetectable in normal adult and fetal livers, but present in all non-hepatic tissues analyzed. Low stringency hybridization experiments revealed the existence of hap related genes in the human genome. The cloned DNA sequence is useful in the preparation of pure hap protein and as a probe in the detection and isolation of complementary DNA and RNA sequences. The hap protein is a retinoic acid (RA) receptor identified as RAR-?.
    Type: Application
    Filed: March 21, 2006
    Publication date: August 24, 2006
    Inventors: Hugues Blaudin de The, Agnes Marchio, Pierre Tiollais, Anne Dejean
  • Publication number: 20040076950
    Abstract: Compositions for the diagnosis of hepatocellular carcinoma (HCC), tumor suppressor genes associated with HCC, methods for diagnosing various forms of HCC, methods for detecting genetic abnormalities associated with HCC, as well as kits for carrying out the methods, are disclosed.
    Type: Application
    Filed: March 28, 2001
    Publication date: April 22, 2004
    Applicants: Institut Pasteur, Institut Nationale de la Sante et de la Recherche Medicale
    Inventors: Anne Dejean, Marie Annick Buendia, Pascal Pineau, Hisaki Nagai
  • Publication number: 20030153740
    Abstract: A previously isolated hepatitis B virus (HBV) integration in a 147 bp cellular DNA fragment linked to hepatocellular carcinoma (HCC) was used as a probe to clone the corresponding complementary DNA from a human liver cDNA library. Nucleotide sequence analysis revealed that the overall structure of the cellular gene, which has been named hap, is similar to that of the DNA-binding hormone receptors. Six out of seven hepatoma and hepatoma-derived cell-lines express a 2.5 kb hap mRNA species which is undetectable in normal adult and fetal livers, but present in all non-hepatic tissues analyzed. Low stringency hybridization experiments revealed the existence of hap related genes in the human genome. The cloned DNA sequence is useful in the preparation of pure hap protein and as a probe in the detection and isolation of complementary DNA and RNA sequences. The hap protein is a retinoic acid (RA) receptor identified as RAR-&bgr;.
    Type: Application
    Filed: December 2, 2002
    Publication date: August 14, 2003
    Applicant: Institut Pasteur
    Inventors: Hugues Blaudin de The, Agnes Marchio, Pierre Tiollais, Anne DeJean
  • Patent number: 6531585
    Abstract: A previously isolated hepatitis B virus (HBV) integration in a 147 bp cellular DNA fragment linked to hepatocellular carcinoma (HCC) was used as a probe to clone the corresponding complementary DNA from a human liver cDNA library. Nucleotide sequence analysis revealed that the overall structure of the cellular gene, which has been named hap, is similar to that of the DNA-binding hormone receptors. Six out of seven hepatoma and hepatoma-derived cell-lines express a 2.5 kb hap mRNA species which is undetectable in normal adult and fetal livers, but present in all nonhepactic tissues analyzed. Low stringency hybridization experiments revealed the existence of hap related genes in the human genome. The cloned DNA sequence is useful in the preparation of pure hap protein and as a probe in the detection and isolation of complementary DNA and RNA sequences. The hap protein is a retinoic acid (RA) receptor identified as RAR-&bgr;.
    Type: Grant
    Filed: February 1, 1991
    Date of Patent: March 11, 2003
    Assignee: Institut Pasteur
    Inventors: Hugues Blaudin de The, Agnes Marchio, Pierre Tiollais, Anne Dejean
  • Publication number: 20030027155
    Abstract: A method for detecting human hepatocellular carcinoma (HCC), wherein the method comprises detecting a homozygous deletion in human chromosome 8p23.
    Type: Application
    Filed: September 13, 2001
    Publication date: February 6, 2003
    Inventors: Anne DeJean, Agnes Marchio, Pascal Pineau
  • Patent number: 6410724
    Abstract: The present invention pertains to new polynucleotides or new combinations of polynucleotides useful as diagnostic tools for predicting the occurrence of a human hepatocellular carcinoma disease. The invention is also directed to polynucleotides that consist in candidate tumor suppressor genes the alteration of which is involved in the occurrence of hepatocellular carcinoma in a patient, as well as to polynucleotides derived from such new candidate tumor suppressor genes and to the corresponding expressed polypeptides. The invention also concerns diagnostic methods using said polynucleotides as diagnostic tools.
    Type: Grant
    Filed: January 21, 2000
    Date of Patent: June 25, 2002
    Assignees: Institut Pasteur, Institut National de la Sante et de la Recherche Medicale (Inserm)
    Inventors: Anne Dejean, Marie-Annick Buendia, Pascal Pineau, Hisaki Nagai, Pierre Tiollais
  • Publication number: 20020042073
    Abstract: The present invention pertains to new polynucleotides or new combinations of polynucleotides useful as diagnostic tools for predicting the occurrence of a human hepatocellular carcinoma disease. The invention is also directed to polynucleotides that consist in candidate tumor suppressor genes the alteration of which is involved in the occurrence of hepatocellular carcinoma in a patient, as well as to polynucleotides derived from such new candidate tumor suppressor genes and to the corresponding expressed polypeptides. The invention also concerns diagnostic methods using said polynucleotides as diagnostic tools.
    Type: Application
    Filed: July 6, 2001
    Publication date: April 11, 2002
    Applicant: INSTITUT PASTEUR
    Inventors: Anne Dejean, Marie-Annick Buendia, Pascal Pineau, Hisaki Nagai, Pierre Tiollais
  • Patent number: 6265161
    Abstract: A method for detecting a predisposition to hepatocellular carcinoma (HCC) using a unique panel of primers for identifying genetic alterations that are linked to HCC, as well as kits for carrying out the methods, are disclosed.
    Type: Grant
    Filed: April 6, 1998
    Date of Patent: July 24, 2001
    Assignee: Institut Pasteur and Institut Nationale de la Sante et de la Recherche Medicale
    Inventors: Anne Dejean, Marie Annick Buendia, Pascal Pineau, Hisaki Nagai
  • Patent number: 5468617
    Abstract: A previously isolated hepatitis B virus (HBV) integration in a 147 bp cellular DNA fragment linked to hepatocellular carcinoma (HCC) was used as a probe to clone the corresponding complementary DNA from a human liver cDNA library. Nucleotide sequence analysis revealed that the overall structure of the cellular gene, which has been named hap, is similar to that of the DNA-binding hormone receptors. Six out of seven hepatoma and hepatoma-derived cell-lines express a 2.5 kb hap mRNA species which is undetectable in normal adult and fetal livers, but present in all non-hepatic tissues analyzed. Low stringency hybridization experiments revealed the existence of hap related genes in the human genome. The cloned DNA sequence is useful in the preparation of pure hap protein and as a probe in the detection and isolation of complementary DNA and RNA sequences. The hap protein is a retinoic acid (RA) receptor identified as RAR-.beta.. The RAR-.beta.
    Type: Grant
    Filed: February 2, 1994
    Date of Patent: November 21, 1995
    Inventors: Hughes Blaudin De The, Agnes Marchio, Pierre Tiollais, Anne DeJean, Nigel Brand, Martin Petkovich, Andree Krust, Pierre Chambon
  • Patent number: 5376530
    Abstract: A previously isolated hepatitis B virus (HBV) integration in a 147 bp cellular DNA fragment linked to hepatocellular carcinoma (HCC) was used as a probe to clone the corresponding complementary DNA from a human liver cDNA library. Nucleotide sequence analysis revealed that the overall structure of the cellular gene, which has been named hap, is similar to that of the DNA-binding hormone receptors. Six out of seven hepatoma and hepatoma-derived cell-lines express a 2.5 kb hap mRNA species which is undetectable in normal adult and fetal livers, but present in all non-hepatic tissues analyzed. Low stringency hybridization experiments revealed the existence of hap related genes in the human genome. The cloned DNA sequence is useful in the preparation of pure hap protein and as a probe in the detection and isolation of complementary DNA and RNA sequences. The hap protein is a retinoic acid (RA) receptor identified as RAR-.beta.. The RAR-.beta.
    Type: Grant
    Filed: July 22, 1993
    Date of Patent: December 27, 1994
    Assignee: Institut Pasteur
    Inventors: Hughes B. De The, Agnes Marchio, Pierre Tiollais, Anne DeJean, Nigel Brand, Martin Petkovich, Andree Krust, Pierre Chambon
  • Patent number: 5317090
    Abstract: A previously isolated hepatitis B virus (HBV) integration in a 147 bp cellular DNA fragment linked to hepatocellular carcinoma (HCC) was used as a probe to clone the corresponding complementary DNA from a human liver cDNA library. Nucleotide sequence analysis revealed that the overall structure of the cellular gene, which has been named hap, is similar to that of the DNA-binding hormone receptors. Six out of seven hepatoma and hepatoma-derived cell-lines express a 2.5 kb hap mRNA species which is undetectable in normal adult and fetal livers, but present in all non-hepatic tissues analyzed. Low stringency hybridization experiments revealed the existence of hap related genes in the human genome. The cloned DNA sequence is useful in the preparation of pure hap protein and as a probe in the detection and isolation of complementary DNA and RNA sequences. The hap protein is a retinoic acid (RA) receptor identified as RAR-.beta.. The RAR-.beta.
    Type: Grant
    Filed: December 11, 1992
    Date of Patent: May 31, 1994
    Assignee: Institut Pasteur
    Inventors: Hughes Blaudin De The, Agnes Marchio, Pierre Tiollais, Anne Dejean, Nigel Brand, Martin Petkovich, Andree Krust, Pierre Chambon
  • Patent number: 5223606
    Abstract: A previously isolated hepatitis B virus (HBV) integration in a 147 bp cellular DNA fragment linked to hepatocellular carcinoma (HCC) was used as a probe to clone the corresponding complementary DNA from a human liver cDNA library. Nucleotide sequence analysis revealed that the overall structure of the cellular gene, which has been named hap, is similar to that of the DNA-binding hormone receptors. Six out of seven hepatoma and hepatoma-derived cell-lines express a 2.5 kb hap mRNA species which is undetectable in normal adult and fetal livers, but present in all non-hepatic tissues analyzed. Low stringency hybridization experiments revealed the existence of hap related genes in the human genome. The cloned DNA sequence is useful in the preparation of pure hap protein and as a probe in the detection and isolation of complementary DNA and RNA sequences.
    Type: Grant
    Filed: December 17, 1987
    Date of Patent: June 29, 1993
    Assignee: Institut Pasteur
    Inventors: Hughes Blaudin de The, Agnes Marchio, Pierre Tiollais, Anne DeJean
  • Patent number: 5149781
    Abstract: A previously isolated hepatitis B virus (HBV) integration in a 147 bp cellular DNA fragment linked to hepatocellular carcinoma (HCC) was used as a probe to clone the corresponding complementary DNA from a human liver cDNA library. Nucleotide sequence analysis revealed that the overall structure of the cellular gene, which has been named hap, is similar to that of the DNA-binding hormone receptors. Six out of seven hepatoma and hepatoma-derived cell-lines express a 2.5 kb hap mRNA species which is undetectable in normal adult and fetal livers, but present in all non-hepatic tissues analyzed. Low stringency hybridization experiments revealed the existence of hap related genes in the human genome. The cloned DNA sequence is useful in the preparation of pure hap protein and as a probe in the detection and isolation of complementary DNA and RNA sequences.
    Type: Grant
    Filed: June 20, 1988
    Date of Patent: September 22, 1992
    Assignee: Institut Pasteur
    Inventors: Hugues Blaudin de THE, Agnes Marchio, Pierre Tiollais, Anne Dejean